Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-402) (NEEDS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01278485
First received: January 13, 2011
Last updated: August 19, 2014
Last verified: August 2014

January 13, 2011
August 19, 2014
May 2011
June 2012   (final data collection date for primary outcome measure)
  • Number of Participants Experiencing Hypoglycemic Episodes in the 6 Months Prior to Enrollment [ Time Frame: Up to 6 Months Prior to Enrollment ] [ Designated as safety issue: No ]
    The participant experience of low blood sugar (hypoglycemia) questionnaire was used to evaluate participants' experience of hypoglycemia during the previous 6 months. Participants were asked to record whether they experienced hypoglycemia symptoms (yes/no) and to record the severity of those symptoms as mild, moderate, severe, or very severe.
  • Number of Participants Experiencing Mild, Moderate, Severe, or Very Severe Hypoglycemic Episodes in the 6 Months Prior to Enrollment [ Time Frame: Up to 6 Months Prior to Enrollment ] [ Designated as safety issue: No ]
    At the time of enrollment, participants were asked to rate their hypoglycemic episodes in the last 6 months as mild, moderate, severe, or very severe. Participants were able to select more than one category.
  • Number of Participants With Hemoglobin A1c <7.0% at the Time of Enrollment [ Time Frame: Day of Enrollment ] [ Designated as safety issue: No ]
    Participant serum samples were collected after an overnight fast to determine the hemoglobin A1c level. Hemoglobin A1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation.
  • Number of hypoglycemic episodes [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Number of participants achieving HbA1C <7% [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01278485 on ClinicalTrials.gov Archive Site
  • Participant Mean Score on the EuroQol-5 Dimension (EQ-5D) Quality-of-Life Questionnaire At the Time of Enrollment [ Time Frame: Day of Enrollment ] [ Designated as safety issue: No ]
    The EQ-5D is a questionnaire that assesses participant quality of life in 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain has 3 levels: no problems, some problems, extreme problems for which participants are asked to self-rate their experience. The EQ-5D total score ranges from -0.171 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome.
  • Participant Mean Score on the EuroQol Visual Analog Scale (EQ-VAS) Quality-of-Life Questionnaire At the Time of Enrollment [ Time Frame: Day of Enrollment ] [ Designated as safety issue: No ]
    Participant health status was self-reported in 5 domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and was analyzed by using visual analog scale (VAS) which records participant responses on a scale of 0 (poor health) to 100 (excellent health).
  • Participant Mean Score on the Treatment Satisfaction Questionnaire for Medication (TSQM) At the Time of Enrollment [ Time Frame: Day of Enrollment ] [ Designated as safety issue: No ]
    The TSQM is a treatment satisfaction questionnaire containing 14 items covering the following dimensions: side effects, effectiveness, convenience, and global satisfaction. Participants were asked to respond in a yes or no fashion, or by using a 5- or 7-point Likert scale. The score for each dimension ranges from 0 to 100, with a higher score expressing a better quality of life.
  • Participant Mean Score on the Self-Reported Adherence and Barriers Questionnaire At the Time of Enrollment [ Time Frame: Day of Enrollment ] [ Designated as safety issue: No ]
    The self-reported adherence and barriers questionnaire to measure treatment compliance asked participants to rate their responses to 5 questions: How often do you take your diabetes medicines exactly as your healthcare provider prescribes them?; During the past 4 weeks, how often were you unsure about some of the things your doctor suggested you do for your diabetes?; During the past 4 weeks, how often were you unable to do what was necessary to follow your doctor's treatment plans for your diabetes?; During the past 4 weeks, how often were you bothered by side effects from your medicines?; and During the past 4 weeks, how often did you have problems getting your prescriptions filled? Participants responded using a scale of 1 to 5, where 1=always, 2=usually, 3=sometimes, 4=rarely, and 5=never.
  • Participant Mean Score on the Worry Scale of Hypoglycemia Fear Survey (HFS II) At the Time of Enrollment [ Time Frame: Day of Enrollment ] [ Designated as safety issue: No ]
    Fear about hypoglycemia during 6 months prior to enrollment was evaluated using the Worry Scale of the HFS II. Responses to the 18-item questionnaire were recorded on a 0 to 4 scale, with 0=never, 1=rarely, 2=sometimes, 3=often, 4=almost always. The total score ranges from 0 to 72, with higher scores indicating increasing fear of hypoglycemia.
  • Number of Participants Experiencing a Change in Body Weight in the 12 Months Prior to Enrollment [ Time Frame: Up to 12 Months Prior to Enrollment ] [ Designated as safety issue: No ]
    Participants were asked to rate their weight change experience in the 12 months prior to enrollment as: weight increased, weight decreased, or weight remained stable.
  • Number of Participants Reporting Body Weight Fears in the 12 Months Prior to Enrollment [ Time Frame: Up to 12 Months Prior to Enrollment ] [ Designated as safety issue: No ]
    On the day of enrollment, participants were asked to rate their fear of gaining weight in the 12 months prior to enrollment using a self-administered questionnaire. The questionnaire elicited responses to 3 statements (I worry about gaining weight; I worry that my diabetic treatment makes me gain weight; and I worry about not being able to stabilize my weight) and relied on a scale of 0 to 4, where 0=never, 1=rarely, 2=sometimes, 3=often, and 4=almost always.
  • European Quality of Life - 5 Dimensions/Visual Analog scale (EQ-5D/EQ-VAS) score [ Time Frame: 1 Day ] [ Designated as safety issue: No ]
  • Treatment Satisfaction Questionnaire for Medication Score (TSQM) [ Time Frame: 1 Day ] [ Designated as safety issue: No ]
  • Self-report Adherence and Barriers Questionnaire Score [ Time Frame: 1 Day ] [ Designated as safety issue: No ]
  • Experience of Low Blood Sugar (Hypoglycemia) Score [ Time Frame: 1 Day ] [ Designated as safety issue: No ]
  • Worry Scale of Hypoglycemia Fear Survey (HFS) II score [ Time Frame: 1 Day ] [ Designated as safety issue: No ]
  • Experience of Weight Gain Score [ Time Frame: 1 Day ] [ Designated as safety issue: No ]
  • Fear of Weight Gain Score [ Time Frame: 1 Day ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-402)
Naturalistic Evaluation of Hypoglycemic Events in Diabetic Subjects

This is a multicenter, observational, retrospective and cross-sectional study to be conducted in a cohort of consecutively selected participants with type 2 diabetes mellitus (T2DM) who have been treated with sulphonylurea (SU) monotherapy or SU + metformin (MF) combination therapy by their cardiologist, nephrologist, or family practice doctor for at least 6 months prior to study enrollment.

The purpose of the study is to assess treatment patterns, goal attainment rates, long-term diabetes complication rates, and frequency and severity of hypoglycemic episodes among T2DM participants treated in cardiology, nephrology and family practice settings.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Adults with Type 2 diabetes mellitus ≥30 years of age who have been treated with sulphonylurea (SU) monotherapy or SU+ merformin (MF) combination therapy for at least 6 months by a cardiologist, nephrologist, or family practice doctor.

Type 2 Diabetes Mellitus
  • Drug: Sulphonylurea
    SU administered according to usual practice.
  • Drug: Metformn
    Metformin administered according to usual practice.
Sulphonylurea (SU) Monotherapy or SU + Metformin
Participants with Type 2 diabetes that have been treated with SU monotherapy for at least 6 months by a cardiologist, nephrologist, or family practice doctor.
Interventions:
  • Drug: Sulphonylurea
  • Drug: Metformn
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
726
June 2012
June 2012   (final data collection date for primary outcome measure)

Inclusion Criteria

  • Participants diagnosed with type 2 diabetes mellitus (DM).
  • Participants at least 30 years of age at time of type 2 DM diagnosis.
  • Participants treated with SU monotherapy or SU + MF combination therapy for at least 6 months prior to enrollment.
  • Participants receiving diabetes care from a cardiologist, nephrologist or family practitioner for at least 6 months.
  • Participants with a clinical record in the health care center.
  • Participants in whose medical records a minimum core data set can be found; core data defined as: age, gender, duration of diabetes/age at diagnosis, all glucose-lowering medications (branded and generic names, dosage, dosing frequency, starting and stopping dates) since the start of all antihyperglycemic medications.

Exclusion Criteria

  • Participants with Type 1 DM.
  • Participants who are pregnant or with gestational DM.
  • Participants receiving any anti-diabetic treatment from an endocrinologist/diabetologist in the previous 6 months.
  • Participants requiring daily concomitant usage of insulin.
  • Participants receiving any other oral diabetes medications other than SU or SU + MF.
  • Participants who are already participating in a clinical trial or other clinical study.
  • Participants for whom it would be impossible to complete the questionnaire.
Both
30 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01278485
0431-402
No
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Director Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP